{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:33:49Z","timestamp":1790573629947,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.seizure.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:31:08Z","timestamp":1736029868000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS)"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotanna","family":"Ezeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Boxx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-5407","authenticated-orcid":false,"given":"Cherry W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.seizure.2025.01.002_bib0001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.seizure.2025.01.002_bib0002","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acschemneuro.3c00613","article-title":"Anticonvulsant classes and possible mechanism of actions","volume":"14","author":"Abd-Allah","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.seizure.2025.01.002_bib0003","unstructured":"Epilepsy Foundation. Which are better: older or newer antiepileptic medications?, https:\/\/www.epilepsy.com\/stories\/which-are-better-older-or-newer-antiepileptic-medications; 2024 [accessed 12 September 2024]."},{"issue":"5","key":"10.1016\/j.seizure.2025.01.002_bib0004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","article-title":"The new antiepileptic drugs: their neuropharmacology and clinical indications","volume":"56","author":"Hanaya","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.002_bib0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.002_bib0006","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2024.05.053","article-title":"Risk factors and drugs associated with the development of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: a population-based cohort study using the Shizuoka Kokuho database","volume":"91","author":"Ubukata","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.seizure.2025.01.002_bib0007","unstructured":"U.S. FOOD & DRUG ADMINSTRATION. Antiseizure Medicines Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and onfi, sympazan (clobazam): drug safety communication - FDA warns of rare but serious drug reaction, https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/antiseizure-medicines-keppra-keppra-xr-elepsia-xr-spritam-levetiracetam-and-onfi-sympazan-clobazam; 28 November 2023 [accessed 12 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0008","unstructured":"U.S. FOOD & DRUG ADMINSTRATION. Questions and answers on FDA's adverse event reporting system (FAERS), https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers; 2018 [accessed 11 Aug 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0009","unstructured":"U.S. FOOD & DRUG ADMINISTRATION. FDA adverse event reporting system (FAERS): latest quarterly data files, https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files; 03 August 2018 [accessed 04 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0010","unstructured":"U.S. FOOD & DRUG ADMINISTRATION. FDA adverse event reporting system (FAERS): latest quarterly data files, https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/instructions-requesting-individual-case-reports; 12 August 2020 [accessed 04 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0011","unstructured":"DRUGBANK Online, https:\/\/go.drugbank.com\/; [accessed 04 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0012","unstructured":"Merative Micromedex, https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/; 2024 [accessed 04 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0013","unstructured":"U.S. FOOD & DRUG ADMINISTRATION. Approved drug products with therapeutic equivalence evaluations | orange book, https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book; 2024 [accessed 04 September 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0014","unstructured":"U.S. FOOD & DRUG ADMINSTRATION. What is a serious adverse event?, https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event; 18 May 2023 [accessed 16 August 2024]."},{"key":"10.1016\/j.seizure.2025.01.002_bib0015","unstructured":"BioPortal. Medical dictionary for regulatory activities terminology (MedDRA), https:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA; 31 January 2024 [accessed 16 August 2024]."},{"issue":"1","key":"10.1016\/j.seizure.2025.01.002_bib0016","doi-asserted-by":"crossref","DOI":"10.23937\/2572-3286.1510023","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) or stevens-johnson syndrome (SJS): does the name matter!","volume":"3","author":"Magbri","year":"2016","journal-title":"J Clin Nephrol Ren Care"},{"issue":"11","key":"10.1016\/j.seizure.2025.01.002_bib0017","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff","year":"2005","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.seizure.2025.01.002_bib0018","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase(\u00ae)","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.002_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.seizure.2025.01.002_bib0020","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3346\/jkms.2020.35.e17","article-title":"Adverse skin reactions with antiepileptic drugs using korea adverse event reporting system database, 2008-2017","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.seizure.2025.01.002_bib0021","first-page":"e33713","article-title":"A comprehensive analysis of topiramate and drug reaction with eosinophilia and systemic symptoms","volume":"15","author":"Thoms","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.seizure.2025.01.002_bib0022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.seizure.2021.07.011","article-title":"Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase\u00ae","volume":"91","author":"Shukla","year":"2021","journal-title":"Seizure"},{"issue":"34","key":"10.1016\/j.seizure.2025.01.002_bib0023","doi-asserted-by":"crossref","first-page":"747","DOI":"10.15585\/mmwr.mm7334a3","article-title":"Reported non-substance-related mental health disorders among persons who died of drug overdose - United States, 2022","volume":"73","author":"Dinwiddie","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T15:09:50Z","timestamp":1769958590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"alternative-id":["S1059131125000044"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS)","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}